(MENAFN- GetNews)
DelveInsight's,
“Castrate Resistant Prostrate Cancer Pipeline Insight, 2024,”
report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Castrate Resistant Prostrate Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Castrate Resistant Prostrate Cancer Pipeline Outlook
Key Takeaways from the Castrate Resistant Prostrate Cancer Pipeline Report
In September 2024:- Bayer - A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC).
DelveInsight's Castrate Resistant Prostrate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostrate Cancer treatment.
The leading Castrate Resistant Prostrate Cancer Companies such as Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma , and others.
Promising Castrate Resistant Prostrate Cancer Therapies such as Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab , and others.
Stay ahead with the most recent pipeline outlook for Castrate Resistant Prostrate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Castrate Resistant Prostrate Cancer Treatment Drugs
Castrate Resistant Prostrate Cancer Emerging Drugs
Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.
Nivolumab: Bristol-Myers Squibb
Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.
Explore groundbreaking therapies and clinical trials in the Castrate Resistant Prostrate Cancer Pipeline. Access DelveInsight's detailed report now! @ New Castrate Resistant Prostrate Cancer Drugs
Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravitreal
Subretinal
Topical.
Molecule Type
Castrate Resistant Prostrate Cancer Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Unveil the future of Castrate Resistant Prostrate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Castrate Resistant Prostrate Cancer Market Drivers and Barriers
Scope of the Castrate Resistant Prostrate Cancer Pipeline Report
Coverage- Global
Castrate Resistant Prostrate Cancer Companies- Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
Castrate Resistant Prostrate Cancer Therapies- Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.
Castrate Resistant Prostrate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Castrate Resistant Prostrate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Castrate Resistant Prostrate Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Castrate Resistant Prostrate Cancer Companies, Key Products and Unmet Needs
Table of Content
Introduction
Executive Summary
Castrate Resistant Prostrate Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Castrate Resistant Prostrate Cancer – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Castrate Resistant Prostrate Cancer Collaboration Deals
Late Stage Products (Phase III)
Niraparib: Janseen
Mid Stage Products (Phase II)
ZEN003694: Newsoara Biopharma
Early Stage Products (Phase I)
EPI7386: ESSA Pharma
Pre-clinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Castrate Resistant Prostrate Cancer Key Companies
Castrate Resistant Prostrate Cancer Key Products
Castrate Resistant Prostrate Cancer- Unmet Needs
Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
Castrate Resistant Prostrate Cancer Analyst Views
Castrate Resistant Prostrate Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
MENAFN19092024003238003268ID1108694688
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.